Back to Search
Start Over
Exelixis Surging 9% on Study Data
- Source :
- MidnightTrader Live Briefs. February 17, 2011
- Publication Year :
- 2011
-
Abstract
- Boston, Feb 17, 2011 (MidnightTrader via COMTEX) -- Exelixis (EXEL) reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in [...]
- Subjects :
- Metastasis -- Research
Analgesics -- Research
Business
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- MidnightTrader Live Briefs
- Publication Type :
- News
- Accession number :
- edsgcl.249328330